Get access

SHORT-TERM EFFECT OF RECOMBINANT HUMAN THYROID-STIMULATING HORMONE ON THYROID VOLUME AND ECHOGENICITY IN HEALTHY BEAGLES

Authors

  • MIGUEL CAMPOS,

    1. Department of Medicine and Clinical Biology of Small Animals, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium
    Search for more papers by this author
  • JIMMY H. SAUNDERS,

    1. Department of Veterinary Medical Imaging and Small Animal Orthopaedics, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium
    Search for more papers by this author
  • LUC DUCHATEAU,

    1. Department of Physiology and Biometrics, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium.
    Search for more papers by this author
  • GEERT PAES,

    1. Department of Medicine and Clinical Biology of Small Animals, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium
    Search for more papers by this author
  • ELKE VAN DER VEKENS,

    1. Department of Veterinary Medical Imaging and Small Animal Orthopaedics, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium
    Search for more papers by this author
  • SYLVIE DAMINET

    1. Department of Medicine and Clinical Biology of Small Animals, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium
    Search for more papers by this author

  • Partially presented as an abstract at Voorjaarsdagen congress in April 2009, Amsterdam, the Netherlands.

Address correspondence and reprint requests to Miguel Campos, at the above address. E-mail: miguelfonseca.campos@ugent.be

Abstract

In humans, administration of recombinant human thyroid stimulating hormone (rhTSH) allows radioactive iodine dose reduction and higher efficacy in the treatment of multinodular goiter and thyroid cancer. A similar effect might be expected in dogs with thyroid carcinoma. However, if rhTSH leads to an increase in thyroid volume, it must be used carefully in dogs with large thyroid tumors to avoid compression of key anatomical structures. The aim of this study was to determine the short-term effect of rhTSH on thyroid volume and echogenicity, measured by ultrasonography, in healthy Beagles. Seven beagles were divided randomly in two groups in a prospective placebo-controlled blinded cross-over study. On day 1, one group received 100 μg of rhTSH intravenously and the other group received placebo. After a wash-out period of 3 weeks, the groups were crossed over. Evaluation of thyroid echogenicity, homogeneity, shape, capsule delineation, and measurement of thyroid length, width, and height were performed by the same observer at baseline, and at 6, 24, and 48 h after injection of rhTSH and placebo. There was no significant difference between the effect of rhTSH and placebo on thyroid volume (P=0.397), echogenicity, homogeneity, or capsule delineation. Time had a significant effect on thyroid volume (P=0.027). No adverse effects after rhTSH administration were noticed. The effect of rhTSH on thyroid volume in dogs with thyroid carcinoma needs to be assessed.

Get access to the full text of this article

Ancillary